1. RE-MODEL and RE-NOVATE : Total VTE and All-cause Mortality
Trials
Dabigatran etexilate
220 mg
dabigatran etexilate
150 mg
enoxaparin
40 mg
RE-NOVATE (Hip) N=
880
874
897
Incidence (%)
53 (6.0)
75 (8.6)
60 (6.7)
Risk ratio over enoxaparin
0.9
1.28
95 % Confidence Interval (CI)
RE-MODEL (Knee)
503
526
512
183 (36.4)
213 (40.5)
193 (37.7)
0.97
1.07
Adapted from Dahl et al. EHA 2008.

2. RE-MODEL and RE-NOVATE : Incidence and Severity of Major Bleeding
Dabigatran etexilate
220 mg
dabigatran etexilate
150 mg
enoxaparin
40 mg
Treated
1 825 (100.0)
1 866 (100.0)
1 848 (100.0)
Major bleeding
33 (1.8)
24 (1.3)
27 (1.5)
Any bleeding
251 (13.8)
258 (13.8)
247 (13.4)
Adapted from Dahl et al. EHA 2008.